Ocugen, Inc. (OCGN) NASDAQ

1.24

-0.02(-1.59%)

Updated at June 09 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Shankar Musunuri	Co-Founder, Chief Executive Officer & Chairman	1.26M	1964
Uday Kompella	Co-founder & Independent Director	61,875	1967
Vijay Tammara	Chief Development Officer	490,915	1960
Ramesh Ramachandran	Chief Accounting Officer & Principal Accounting Officer	504,925	1968
Huma Qamar	Chief Medical Officer	644,027	1984
Arun Upadhyay	Chief Scientific Officer and Head of Research & Development	703,751	1982
Mohamed Genead	Interim Chief Medical Officer	0	N/A
Jyothy Pillai	Vice President & Head of Regulatory & Quality	0	N/A
Kristen Craft	Head of People & Culture	0	N/A
Rita Johnson-Greene	CFO & Principal Accounting Officer	0	1977
Tiffany Hamilton	AVP & Head of Corporate Communications	0	N/A
Durgaprasad Annavajjula	Vice President, Head of Program Management & Chief of Staff	0	N/A
Paul Staid	Executive Vice President of Operations	0	N/A
John Kouch	General Counsel	0	N/A

Name

Title

Pay

Year Born

Shankar Musunuri

Co-Founder, Chief Executive Officer & Chairman

1.26M

1964

Uday Kompella

Co-founder & Independent Director

61,875

1967

Vijay Tammara

Chief Development Officer

490,915

1960

Ramesh Ramachandran

Chief Accounting Officer & Principal Accounting Officer

504,925

1968

Huma Qamar

Chief Medical Officer

644,027

1984

Arun Upadhyay

Chief Scientific Officer and Head of Research & Development

703,751

1982

Mohamed Genead

Interim Chief Medical Officer

N/A

Jyothy Pillai

Vice President & Head of Regulatory & Quality

N/A

Kristen Craft

Head of People & Culture

N/A

Rita Johnson-Greene

CFO & Principal Accounting Officer

1977

Tiffany Hamilton

AVP & Head of Corporate Communications

N/A

Durgaprasad Annavajjula

Vice President, Head of Program Management & Chief of Staff

N/A

Paul Staid

Executive Vice President of Operations

N/A

John Kouch

General Counsel

N/A

Description

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.